Equillium Inc
equilliumbio.comWhat Do They Do?
Develops experimental medicines for patients with severe autoimmune and inflammatory disorders, including gastrointestinal and lung diseases.
10-K for FY2025, filed Mar 25, 2026We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to…View ↗
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial…View ↗
EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. Inhibiting…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$4.7MView ↗
- ▼ −18% (Loss)
- vs −$5.7M in Q2 FY2025
Pipeline focus
The older report describes active clinical programs across its immunology pipeline; the latest instead centers development on preclinical therapies for gastrointestinal and inflammatory lung diseases.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to…View ↗
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial…View ↗
EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. Inhibiting…View ↗
Loading...
